HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Defends Aspirin Leadership While Eyeing Top OTC Spot

This article was originally published in The Tan Sheet

Executive Summary

Bayer boosted its marketing spend for aspirin during the third quarter in an effort to fend off competition in the cardio-aspirin category

You may also be interested in...



Aspirin Labeling Should Reflect Risk-Based CVD Prevention, Bayer Says

Aspirin therapy labeling should be revised to include an indication for primary prevention of myocardial infarction, reflecting a risk-based approach to cardiovascular disease prevention, Bayer maintains in a recent submission to FDA

Bayer Dealt Setback in Alka-Seltzer PPA Case

A jury award in favor of a plaintiff who used phenylpropanolamine-containing Alka-Seltzer may not bode well for Bayer in its ongoing PPA litigation

People In Brief

Perrigo promotes in pricing, planning

Topics

UsernamePublicRestriction

Register

RS128116

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel